Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

PURPOSE: CLL cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL. EXPERIMENTAL DESIGN: Patients were eligible for this phase 2 trial if they had documented CLL/SLL and had failed a...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Amrein, Philip C., Attar, Eyal C., Takvorian, Tak, Hochberg, Ephraim P., Ballen, Karen K., Leahy, Kathleen M., Fisher, David C., LaCasce, Ann S., Jacobsen, Eric D., Armand, Philippe, Hasserjian, Robert P., Werner, Lillian, Neuberg, Donna, Brown, Jennifer R.
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108904/
https://ncbi.nlm.nih.gov/pubmed/21402714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2879
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы